Palivizumab对呼吸道合胞病毒感染预防儿童患有囊性纤维化。

文章的细节

引用

复制到剪贴板

罗宾逊KA, Odelola OA、沙尔丹哈我McKoy N

Palivizumab对呼吸道合胞病毒感染预防儿童患有囊性纤维化。

科克伦数据库系统启2010年2月17日;(2):CD007743。cd007743.pub2 doi: 10.1002/14651858.。

PubMed ID

20166098 (在PubMed

]

文摘

背景:呼吸道合胞体病毒(RSV)感染导致婴幼儿急性肺部感染在世界范围内,导致相当大的发病率和死亡率。囊性纤维化(CF)的孩子容易复发性肺部炎症,细菌殖民化和随后的慢性呼吸道疾病,使他们严重RSV感染的风险需要重症监护和呼吸支持。目前治疗不存在,因此预防是非常重要的。Palivizumab有效地减少了RSV住院率和建议预防高危儿童与其他条件。目前还不清楚如果palivizumab可以预防RSV住院治疗上并与CF儿童重症监护室招生。目的:确定的疗效和安全性palivizumab (Synagis ((R)))与安慰剂相比,没有预防或其他预防措施,对预防RSV感染时,这些患儿住院和死亡率CF。搜索策略:我们搜查了Cochrane CF和遗传疾病组试验合格的注册和扫描引用研究和相关评论。最后搜索:2010年1月20日。选择标准:随机和quasi-randomised研究。数据收集和分析:作者独立提取数据和评估偏差的风险。主要结果:一项研究(186名婴儿两岁)比较5月剂量的palivizumab (N = 92)安慰剂(N = 94)在一个赛季RSV是识别和满足我们的入选标准。在6个月随访,一个参与者在每组住院是因为RSV;在两组没有死亡。 In the palivizumab and placebo groups, 86 and 90 children experienced any adverse event, while 5 and 4 children had related adverse events respectively. Nineteeen children receiving palivizumab and 16 receiving placebo suffered serious adverse events; one participant receiving palivizumab discontinued due to this. At 12 months follow-up, there were no significant differences between groups in number of Pseudomonas bacterial colonisations or change in weight-to-height ratio. AUTHORS' CONCLUSIONS: We identified one randomised controlled trial comparing five monthly doses of palivizumab to placebo in infants up to two years old with CF. While the overall incidence of adverse events was similar in both groups, it is not possible to draw conclusions on the safety and tolerability of RSV prophylaxis with palivizumab in infants with CF because the trial did not specify how adverse events were classified. Six months after treatment, the authors reported no clinically meaningful differences in outcomes; however no data were provided. Additional randomised studies are needed to establish the safety and efficacy of palivizumab in children with CF.

beplay体育安全吗DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Palivizumab	融合糖蛋白F0	蛋白质	人类呼吸道合胞体病毒B(18537株)	是的	不可用	细节